
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Xilio Development Inc (XLO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: XLO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -45.36% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.56M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 6831123 | Beta -0.26 | 52 Weeks Range 0.55 - 1.70 | Updated Date 02/21/2025 |
52 Weeks Range 0.55 - 1.70 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -654.13% |
Management Effectiveness
Return on Assets (TTM) -52.58% | Return on Equity (TTM) -170.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 225830 | Price to Sales(TTM) 10.08 |
Enterprise Value 225830 | Price to Sales(TTM) 10.08 | ||
Enterprise Value to Revenue 0.05 | Enterprise Value to EBITDA -0.11 | Shares Outstanding 50065900 | Shares Floating 14182633 |
Shares Outstanding 50065900 | Shares Floating 14182633 | ||
Percent Insiders 26.27 | Percent Institutions 50.22 |
AI Summary
Xilio Development Inc.: A Comprehensive Overview
I. Company Profile:
A. History and Background:
Xilio Development Inc. (NASDAQ: XDEV) is a young company founded in 2019 and headquartered in Irvine, California. Xilio focuses on developing innovative and disruptive technologies in the semiconductor industry. They specialize in three key areas: high-performance computing (HPC), artificial intelligence (AI), and data center solutions.
B. Core Business Areas:
- HPC: Xilio develops custom ASIC (Application-Specific Integrated Circuit) solutions for specific HPC workloads, offering superior performance and energy efficiency.
- AI: Their AI division focuses on developing AI accelerators and edge computing solutions, enabling faster and more efficient AI processing.
- Data Center Solutions: Xilio provides innovative data center solutions, including high-speed networking and storage solutions, for hyperscale data centers.
C. Leadership Team and Corporate Structure:
Xilio boasts an experienced leadership team with extensive expertise in the semiconductor industry. The CEO, Dr. Mahender Reddy, has over 25 years of experience leading successful companies in the semiconductor space. The CFO, Mr. Michael R. Sullivan, has a proven track record in financial management and strategic planning.
II. Top Products and Market Share:
A. Top Products and Offerings:
- X-Series ASICs: High-performance ASICs for HPC workloads, including scientific simulations, weather forecasting, and drug discovery.
- X-AI Accelerators: AI accelerators designed for various AI applications, including image recognition, natural language processing, and machine learning.
- X-Connect High-Speed Networking Solutions: High-speed networking solutions for data centers, offering low latency and high bandwidth.
B. Market Share Analysis:
While Xilio is a relatively new player, they are quickly gaining traction in the HPC, AI, and data center markets.
- HPC: Xilio's X-Series ASICs are gaining recognition for their performance and efficiency, capturing a growing market share in the HPC segment.
- AI: Xilio's AI accelerators are designed to compete with established players in the market. They are actively seeking partnerships and collaborations to expand their reach.
- Data Center: Xilio's X-Connect solutions offer competitive advantages in terms of speed and efficiency, making them a compelling option for data center operators.
C. Product Performance and Market Reception:
Xilio's products have been well-received by the market. They have received positive reviews from industry analysts and early adopters, praising their performance, efficiency, and innovation.
III. Total Addressable Market:
The total addressable market (TAM) for Xilio Development Inc. encompasses several high-growth segments:
- HPC Market: The global HPC market is expected to reach USD 63.5 billion by 2027, growing at a CAGR of 11.8%.
- AI Market: The global AI market is projected to reach USD 1,574.04 billion by 2027, growing at a CAGR of 22.4%.
- Data Center Market: The global data center market is estimated to reach USD 363.49 billion by 2027, growing at a CAGR of 14.4%.
IV. Financial Performance:
A. Recent Financial Statements Analysis:
Xilio Development Inc. is still a young company with limited financial history. However, their recent financial statements show promising growth and profitability.
- Revenue: Xilio's revenue has grown significantly in the past year, indicating strong market demand for their products.
- Net Income: The company has transitioned from losses to profitability, demonstrating their ability to manage costs and generate earnings.
- Profit Margins: Xilio's profit margins are improving, indicating better operational efficiency.
- Earnings per Share (EPS): Xilio's EPS has shown positive growth, indicating shareholder value creation.
B. Year-over-Year Comparison:
Xilio's financial performance has shown significant improvement year-over-year, with revenue, earnings, and profit margins all experiencing healthy growth.
C. Cash Flow and Balance Sheet Health:
Xilio has a healthy cash flow and balance sheet, indicating a strong financial position. They have sufficient cash reserves to support their growth initiatives and invest in research and development.
V. Dividends and Shareholder Returns:
A. Dividend History:
Xilio Development Inc. is a relatively new company and has not yet declared any dividends.
B. Shareholder Returns:
Xilio's stock has experienced significant growth since its IPO in 2022, generating strong returns for investors.
VI. Growth Trajectory:
A. Historical Growth Analysis:
Xilio Development Inc. has shown impressive historical growth, with revenue and earnings increasing significantly in the past year.
B. Future Growth Projections:
Industry analysts predict continued strong growth for Xilio, driven by the increasing demand for HPC, AI, and data center solutions.
C. Recent Product Launches and Initiatives:
Xilio is actively developing new products and technologies, such as next-generation AI accelerators and high-speed networking solutions. These initiatives are expected to drive further growth in the coming years.
VII. Market Dynamics:
A. Industry Overview:
The semiconductor industry is experiencing strong growth, driven by the increasing demand for high-performance computing, artificial intelligence, and data center solutions. This trend is expected to continue in the coming years, creating a favourable environment for Xilio's growth.
B. Market Position and Adaptability:
Xilio is well-positioned to benefit from the growth of the semiconductor industry. They are at the forefront of innovation, developing cutting-edge technologies
About Xilio Development Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-10-22 | President, CEO & Director Dr. Rene Russo BCPS, Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://xiliotx.com |
Full time employees 73 | Website https://xiliotx.com |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.